Preferred Label : tamsulosin hydrochloride;
UMLS semantic type : T109 - Organic Chemical; T121 - Pharmacologic Substance;
CAS number : 106463-17-6; 11SV1951MR;
Is substance : O;
UNII : 11SV1951MR;
InChIKey : ZZIZZTHXZRDOFM-XFULWGLBSA-N;
Origin ID : M0397906;
UMLS CUI : C0771774;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Exact mapping(s) to DCI
- YM 617 [International Nonproprietary Name]
- Related record
- Semantic type(s)
- UMLS correspondences (same concept)
- YM 617 [International Nonproprietary Name]
https://www.has-sante.fr/jcms/p_3476380/fr/vecalmys-succinate-de-solifenacine-/-chlorhydrate-de-tamsulosine-troubles-urologiques
2023
false
false
false
France
administration, oral
drug combinations
treatment outcome
insurance, health, reimbursement
tamsulosin and solifenacin
urinary incontinence, urge
Urinary Frequency
Enlarged Prostate with Lower Urinary Tract Symptoms
prostatic hyperplasia
urological agents
evaluation of the transparency committee
tamsulosin hydrochloride
Tamsulosin
Solifenacin Succinate
---
https://www.has-sante.fr/portail/jcms/c_2775796/fr/josir-mecir
https://www.has-sante.fr/portail/jcms/c_1278892/josir-mecir
https://www.has-sante.fr/portail/jcms/c_539602/fr/josir-mecir
2017
false
France
French
treatment outcome
Delayed-Action preparations
administration, oral
sulfonamides
tamsulosin
prostatic hyperplasia
insurance, health, reimbursement
adrenergic alpha-1 receptor antagonists
tamsulosin hydrochloride
evaluation of the transparency committee
Tamsulosin
---
http://www.has-sante.fr/portail/jcms/c_2741821/fr/combodart
http://www.has-sante.fr/portail/jcms/c_2741821/fr/combodart-dutasteride-tamsulosine-inhibiteur-de-la-5-reductase-alpha-bloquant
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug combinations
administration, oral
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
5-alpha reductase inhibitors
5-alpha reductase inhibitors
Dutasteride
Dutasteride
tamsulosin and dutasteride
prostatic hyperplasia
tamsulosin hydrochloride
tamsulosin hydrochloride
treatment outcome
insurance, health, reimbursement
urinary retention
prostatic hypertrophy, benign
urological agents
urological agents
sulfonamides
sulfonamides
Tamsulosin
Tamsulosin
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61103520
2012
France
summary of product characteristics
package leaflet
tamsulosin hydrochloride
capsules
Tamsulosin
---
http://www.has-sante.fr/portail/jcms/c_1298559/combodart
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/combodart_05092012_avis_ct9291.pdf
2012
false
France
French
Dutasteride
Dutasteride
Tamsulosin
Tamsulosin
tamsulosin and dutasteride
administration, oral
adult
aged
drug combinations
insurance, health, reimbursement
prostatic hyperplasia
prostatic hyperplasia
sulfonamides
sulfonamides
urinary retention
treatment outcome
clinical trials, phase iii as topic
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
5-alpha reductase inhibitors
5-alpha reductase inhibitors
tamsulosin hydrochloride
tamsulosin hydrochloride
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/display.jsp?id=c_539618
http://www.has-sante.fr/portail/jcms/c_1281717/omix-omexel
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-08/omix_omexel_18072012_avis_ct12128.pdf
2012
France
French
administration, oral
Delayed-Action preparations
sulfonamides
insurance, health, reimbursement
tamsulosin
prostatic hyperplasia
adrenergic alpha-1 receptor antagonists
tamsulosin hydrochloride
treatment outcome
evaluation of the transparency committee
Tamsulosin
---
http://www.has-sante.fr/portail/display.jsp?id=c_400904
2006
France
evaluation of the transparency committee
tamsulosin hydrochloride
Tamsulosin
---
